Nine Vanderbilt University faculty members have been elected fellows of the American Association for the Advancement of Science this year.

Kamakoti “Kami” Bhat, a fifth-year graduate student in the lab of David Cortez, Ph.D., professor of Biochemistry in the School of Medicine, has achieved a “first” for Vanderbilt University.

Vanderbilt-Ingram Cancer Center (VICC) is leading a Phase 3 global trial of a cancer therapy that was initially tested and validated in a VICC research laboratory. One of the first patients treated with the therapy came to VICC after a bump on the head led to an unexpected cancer diagnosis.

William Tansey, Ph.D., professor of Cell Development and Biology and Ingram Professor of Cancer Research, has been awarded a two-year, $250,000 grant from Alex’s Lemonade Stand Foundation (ALSF) to study malignant rhabdoid tumors (MRTs).

A consortium led by Vanderbilt University Medical Center (VUMC) researchers has received funding as it makes plans for a multicenter trial that could determine whether deep brain stimulation (DBS) slows the progression of Parkinson’s disease in early-stage patients.

In 2013, Vanderbilt University School of Medicine (VUSM) received one of 10 grants from the National Institutes of Health called BEST (Broadening Experiences in Scientific Training) to help train scientists for a variety of diverse careers.

The Robert J. Kleberg Jr. and Helen C. Kleberg Foundation has awarded a $3 million grant to Vanderbilt-Ingram Cancer Center (VICC) investigators in support of VICC’s drug discovery program. The gift awarded over the next three years from the private, San Antonio, Texas-based foundation will enable VICC researchers to pursue the development of new compounds to block the activity of cancer-causing genes and proteins that had previously been considered “undruggable.”